In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction Read More »
Phase 1b study of Bavdegalutamide, an androgen receptor PROTAC® degrader, combined with abiraterone in patients with metastatic prostate cancer Read More »
Phase 1/2 Study of ARV-110, an Androgen Receptor PROTAC® Degrader, in Metastatic Castration-Resistant Prostate Cancer Read More »
Discovery of ARV-110, a first in class androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer Read More »
